

**Network-linked neurodegenerative patterns:** Drzezga looks at growing evidence that neurodegenerative disorders are characterized by the spread of specific molecular neuropathologic features along neuronal brain networks and examines associated imaging techniques, network overlaps, and potential causative relationships. . . . **Page 1645**

**Interventional oncology and the liver:** Voutsinas and colleagues provide an educational overview of indications for  $^{90}\text{Y}$  radioembolization, the roles of preprocedural angiography and  $^{99\text{m}}\text{Tc}$ -macroaggregated albumin scans, different dosing techniques, types of microspheres, and potential complications. . . . **Page 1649**

**$^{43,44}\text{Sc}$ ,  $^{52}\text{Mn}$ , and  $^{45}\text{Ti}$ :** Chapple and Lapi describe the characteristics of these emerging metal radionuclides and their potential as new PET agents. . . . **Page 1655**

**PET and cerebral small vessel disease:** Heiss details the advantages of functional information from the addition of  $^{18}\text{F}$ -FDG PET to current diagnostic imaging in cerebral small vessel disease, including differentiation of vascular and degenerative cognitive impairment. . . . **Page 1660**

**$\text{NaF}$  and PSMA PET/CT:** Harmon and colleagues compare the diagnostic performance of  $^{18}\text{F}$ -DCFB, a first-generation prostate-specific membrane antigen (PSMA)-targeted agent, and  $^{18}\text{F}$ - $\text{NaF}$ , a sensitive marker of osteoblastic activity, in PET/CT imaging in patients with metastatic prostate cancer. . . . **Page 1665**

**$^{11}\text{C}$ -Choline dynamic PET in PCa:** Grkovski and colleagues investigate the value of pharmacokinetic modeling for quantifying  $^{11}\text{C}$ -choline uptake in patients with clinically suspected recurrent prostate cancer. . . . **Page 1672**

**$\alpha_v\beta_6$  integrin-binding peptides:** Roesch and colleagues analyze the affinity and specificity of 5 native  $\alpha_v\beta_6$  integrin-specific binders in comparison to SFITGv6, a novel potential tracer for imaging and targeted therapy of  $\alpha_v\beta_6$  integrin-positive carcinomas. . . . **Page 1679**

**c-Met-targeted imaging:** Han and colleagues report on preclinical studies with  $^{99\text{m}}\text{Tc}$ -HYNIC-cMBP, a c-Met-binding peptide radiotracer for SPECT imaging, with promise for clinical selection and monitoring of non-small cell lung cancer for c-Met-responsive therapy. . . . **Page 1686**

**$^{90}\text{Y}$ -DOTATOC dosimetry:** Menda and colleagues describe a dosimetric method for  $^{90}\text{Y}$ -DOTATOC using  $^{90}\text{Y}$ -DOTATOC PET/CT and bremsstrahlung SPECT/CT and determine whether dosimetry-based administered activities differ significantly from standard doses. . . . **Page 1692**

**PRRT with  $^{177}\text{Lu}$ -DOTA-EB-TATE:** Zhang and colleagues present the results of a first-in-human study exploring the safety and dosimetry of this long-acting radiolabeled somatostatin analog with promise for peptide receptor radionuclide therapy for neuroendocrine tumors. . . . **Page 1699**

**Radiopharmaceutical therapy now:** Divgi offers perspective on the importance of broad clinical rigor in radiopharmaceutical clinical practice and previews an article in this issue of *JNM* on  $^{131}\text{I}$ -MIBG for metastatic neuroendocrine tumors. . . . **Page 1706**

**Survival after  $^{131}\text{I}$ -MIBG therapy:** Kane and colleagues provide a retrospective analysis identifying predictors of survival in patients with MIBG-positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumors treated with  $^{131}\text{I}$ -MIBG therapy. . . . **Page 1708**

**$^{68}\text{Ga}$ -PSMA-11 PET/CT for RT planning:** Calais and colleagues determine how often definitive radiation treatment planning based on standard target volumes covers  $^{68}\text{Ga}$ -PSMA-11 PET/CT-defined disease and assess the potential impact of  $^{68}\text{Ga}$ -PSMA-11 PET/CT on definitive planning. . . . **Page 1714**

**PET in Huntington disease:** Bertoglio and colleagues use  $^{11}\text{C}$ -ABP688 PET imaging to longitudinally characterize in vivo changes in metabotropic glutamate receptor 5 in a mouse model of Huntington disease. . . . **Page 1722**

**$^{123}\text{I}$ -MIBG scintigraphy and wearing-off in PD:** Lee and colleagues investigate whether cardiac sympathetic denervation increases the risk of the early wearing-off phenomenon in Parkinson disease. . . . **Page 1728**

**PET/CT in cyst infection in ADPKD:** Pijl and colleagues assess the value of  $^{18}\text{F}$ -FDG PET/CT for diagnosing renal or hepatic cyst infection in patients with autosomal dominant polycystic kidney disease. . . . **Page 1734**

**Cost and bone SPECT/CT in TKA:** Wyngaert and colleagues quantify the economic value of bone SPECT/CT and CT or metal artifact reduction-sequence MR imaging for diagnostic assessment of recurrent moderate-to-severe pain after total knee arthroplasty. . . . **Page 1742**

**$^{124}\text{I}$ -DPA-713 PET/CT clinical studies:** Foss and colleagues detail biodistribution and radiation dosimetry of this radioligand for the 18-kDa translocator protein in healthy individuals and discuss its potential in imaging of macrophage-associated inflammation. . . . **Page 1751**

**Multispectral surgical guidance:** Meerhoek and colleagues describe preclinical studies with a multispectral fluorescence guidance approach that enables discrimination between prostate-draining and lower-limb-draining lymph nodes in prostate cancer surgery. . . . **Page 1757**

**Rebinning with rigid motion correction:** Reilhac and colleagues implement an accurate list-mode-based rigid motion correction method for PET data acquired with the mMR synchronous PET/MR scanner and optimize correction for  $^{11}\text{C}$ -Pittsburgh compound B scans. . . . **Page 1761**

**PET spatial resolution:** Lodge and colleagues introduce a technique that can be used to measure the spatial resolution that can be expected with clinical PET protocols, potentially providing more relevant estimates than are typically obtained with established experimental procedures. . . . **Page 1768**